NorthStar Medical Radioisotopes said it's making progress on an initiative to increase its production capacity for molybdenum-99 (Mo-99).
Construction is underway on the firm's 20,000-sq-ft expansion to its headquarters facility in Beloit, WI. Once dissolution and filling equipment is installed, qualified, validated, and approved by the U.S. Food and Drug Administration (FDA), the expansion will more than double the company's capacity to fill Mo-99 source vessels, NorthStar said.
The firm received FDA approval in 2018 to manufacture its RadioGenix isotope separation system, which can produce technetium-99m from nonuranium-based Mo-99.
In addition, NorthStar said it's nearing final validation of two source-vessel filling systems at its facility in Columbia, MO.
